Thursday, 21 October 2021


Cerba Research, ACT Genomics bring precision medicine offering to Asia

24 August 2021 | News

Purpose-built facility in Taiwan to enable precision medicine

image credit- shutterstock

image credit- shutterstock

Belgium-based Cerba Research, owned by Cerba HealthCare, has joined forces with ACT Genomics under a joint venture model to create a purpose-built lab facility in Taiwan covering the Asia Pacific region.

This expansion of the precision medicine offering includes central labs, flow cytometry, histopathology, and translational science laboratory services. Deep scientific expertise from both sides of this strategic alliance will support new growth areas for biotech and pharma clients globally and drive better patient outcomes across all phases of clinical trials.

The expansion includes investments in a new facility in Taipei (Taiwan) and state-of-the-art technologies to strengthen capabilities and services offered to our clients on a truly global scale:

  • Cutting-edge flow cytometry technologies
  • Exploratory as well as In Vitro Diagnostic histopathology services
  • Peripheral blood mononuclear cell (PBMC) isolations from blood and soft tissues

Progress on construction, technology transfers, and expansion of the scientific team will enable the CerbACT Asia Laboratory to be fully operational in September 2021.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account